Safety of TG100-115 for Heart Attack Treated With Angioplasty

Completed · Phase 1/Phase 2

Conditions studied: Myocardial Infarction

In brief

TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow. We will also evaluate whether TG100-115 reduces heart muscle damage.

Key facts

Study ID

NCT00103350

Run by

TargeGen

People needed

100

Starts

2005-01-01

Expected to finish

2008-01-01

Last updated by the study team

2008-05-20

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 yrs
• ECG patterns consistent with an acute anterior myocardial infarction with ST segment elevation of 2mm in two contiguous ECG leads among leads V1-V4.
• Have prolonged, continuous (lasting at least 20 mins) signs and symptoms of myocardial ischemia not eliminated with nitrates.
• Intent to proceed to primary PCI within 6 hours of chest pain onset
• Sign an informed consent form and be willing to attend follow-up visits for safety and other study assessments.

You may not qualify if…

• Female of childbearing potential.
• History of previous myocardial infarction.
• History of congestive heart failure.
• Requirement for a cardiac pacemaker or defibrillator.
• Cardiogenic shock.
• Patients previously treated with thrombolytic therapy.
• Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease.

Where it is running

• David Holmes, MD — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.